Copyright thehindubusinessline
Aurobindo Pharma’s consolidated net profit increased 3.8 per cent to ₹848 crore in the second quarter of the current financial year ended September 30, 2025, compared to ₹817 crore in the corresponding quarter of the previous fiscal. The total revenue of the Hyderabad-based company grew 6.3 per cent to ₹8,286 crore against ₹7,796 crore in the year-ago period. “Q2 has been another steady quarter for Aurobindo, demonstrating the resilience of our base business and the depth of our product portfolio. We continue to see healthy demand across key markets, with our US and Europe businesses performing in line with expectations,’’ said K Nithyananda Reddy, Vice-Chairman and Managing Director, Aurobindo Pharma, in a release on Wednesday. “The balance between growth and profitability remains central to our execution. With the momentum we’ve built and all strategic initiatives progressing as planned, we are confident of meeting our annual guidance and sustaining long-term value creation,’’ Reddy added. Revenue from the US formulations increased 3.1 per cent y-o-y to ₹3,638 crore, while for Europe it grew 17.8 per cent to ₹2,480 crore. Revenue from the growth markets registered 8.7 per cent increase at 882 crore, the company said. The Research & Development (R&D including depreciation) spend was ₹414 crore amounting to 5 per cent of revenues. Published on November 5, 2025
